The use of pregabalin without prescription

Soldatkin V.A.

GBOU VPO "Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava Rossii, Rostov-na-Donu

Liubchenko D.A.

GBUZ "Narkologicheskiĭ dispanser", Krasnodar

Svetlichnaia E.V.

GBUZ "Narkologicheskiĭ dispanser", Krasnodar

Riabkina E.A.

GBOU VPO "Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet", Rostov-na-Donu

The use of pregabalin without prescription

Authors:

Soldatkin V.A., Liubchenko D.A., Svetlichnaia E.V., Riabkina E.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2): 37‑39

DOI: 10.17116/jnevro201411411237-39

Downloaded: 24

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Soldatkin VA, Liubchenko DA, Svetlichnaia EV, Riabkina EA. The use of pregabalin without prescription. S.S. Korsakov Journal of Neurology and Psychiatry. 2014;114(11‑2):37‑39. (In Russ.)
https://doi.org/10.17116/jnevro201411411237-39

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Close metadata

Recommended articles:

Xenon inhalation in persons with burdened alcohol past medical history: a series of cases from expert practice. Forensic Medical Expertise. 2024;(5):42-50

Objective. Interest to pregabalin can be explained by the fact that the drug is purchased without prescription and used in nonmedical purposes. Authors performed the identification of pregabalin in the biological material (urine) of 16 364 patients. Material and methods. Psychoactive substances were identified in a chemical-toxicological laboratory of a narcological dispensary in the Krasnodar region. Results and conclusion. Pregabalin was identified only in 0.1% of the patients. In all cases it was not used for the first time. Most often pregabalin was used to relieve abstinent syndrome in different types of addictions. The mechanisms of its action in these cases and potential danger of using without prescription are considered.

Keywords:

pregabalin

causation

addiction

non-medical application

Authors:

Soldatkin V.A.

GBOU VPO "Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet" Minzdrava Rossii, Rostov-na-Donu

Liubchenko D.A.

GBUZ "Narkologicheskiĭ dispanser", Krasnodar

Svetlichnaia E.V.

GBUZ "Narkologicheskiĭ dispanser", Krasnodar

Riabkina E.A.

GBOU VPO "Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet", Rostov-na-Donu

List of references:

Syunyakov T.S., Syunyakov S.A., Morozov P.V. Obzor effektivnosti pregabalina pri generalizovannom trevozhnom rasstroistve s pozitsii ego spektral'noi kharakteristiki. Psikhiatriya i psikhofarmakoterapiya 2013; 15: 1: 94-100.
Lydiard R.B., Rickels K., Herman B., Feltner D.E. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13: 2: 229-241.
Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., Young J.P. Jr., LaMoreaux L.K., Martin S.A., Sharma U. Pregabalin for the treatment of fibromyalgia syndrome. Arthr Rheum 2005; 52: 1264-1273.
Pulman J., Hemming K., Marson A.G. Pregabalin add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2014; CD005612. DOI: 10.1002/14651858.CD005612. Rub 3.
Rosenstock J., Tuchman M., La Moreaux L., Sharma U. Pregabalin for the treatment of painfull diabetic peripheral neuropathy: a double-blind, placebo-controlled trail. Pain 2004; 110: 628-638.
Wood D.M., Green J.L., Le Lait M.-C., Dargan P.I. Is there evidence of misuse of Baclofen, Gabapentin and Pregabalin in the United Kingdom (UK)? Clinical Toxicology 2013; 51: 663.
Bobes J., Rubio G., Teran A. et al. Pregabalin for the discontinuation of longterm Benzodiazepines use: An assessment of its effectiveness in daily clinical practice. European Psychiatry 2012; 27: 301-307.
Martinotti G., Di Nicola M., Frustaci A. et al. Pregabalin, Tiapride and Lorazepam in alcohol withdrawal syndrome: A multi-centre, randomized, single-blind comparison trial. Addiction 2010; 105: 288-299.
Di Nicola M., Martinotti G., Tedeschi D. et al. Pregabalin in outpatient detoxification of subjects with mild-to-moderate alcohol withdrawal syndrome. Human Psychopharmacology 2010; 25: 268-275.
Chiechio S., Zammataro M., Caraci F., Rampello L., Copani A., Sabato A.F., Nicoletti F. Pregabalin in the treatment of chronic pain. Clin Drug Invest 2009; 29: 3: 203-213.
Field M.J., Cox P.J., Stott E., Melrose H., Offord J., Su T.Z., Bramwell S., Corradini L., England S., Winks J., Kinloch R.A., Hendrich J., Dolphin A.C., Webb T., Williams D. Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. Proc Natl Acad Sci USA 2006; 14: 103: 46: 17537-17542.
Fehrenbacher J.C., Taylor C.P., Vasko M.R. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105: 1-2: 133-141.
Murphy T.K., Young J.P., LaMoreaux L.B. Efficacy, safety, and tolerability of pregabalin as treatment of chronic peripheral neuropathic pain syndromes: pooled analysis of 11 randomized clinical trials in painful DPN and PHN. Eur J Neurol 2007; 14: Suppl 1: 265-266.
Portenoy R., Murphy T.K., Young J., Griesing T. Pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia: onset and duration of analgesia in combined analyses of clinical studies. Poster presented at the 25th Annual Scientific Meeting of the American Pain Society: May 3-6, 2006; San Antonio.

Close metadata